Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Type D Personality and Life Satisfaction in Bipolar Disorder Type 2 and Major Depressive Disorder

25 giugno 2026 aggiornato da: Mehmet Hamdi ÖRÜM, Elazığ Mental Health and Diseases Hospital

Examination of Type D Personality and Factors Associated With Life Satisfaction in Parents of Patients Diagnosed With Bipolar Disorder Type 2 and Major Depressive Disorder

Bipolar Disorder Type II (BD-II) and Major Depressive Disorder (MDD) are common mood disorders associated with substantial psychological distress, impaired functioning, and reduced quality of life. BD-II is characterized by recurrent major depressive episodes and hypomanic episodes, whereas MDD is characterized by one or more major depressive episodes without a history of mania or hypomania. Both disorders have a significant genetic component, and family studies suggest that first-degree relatives may exhibit subclinical affective traits, personality characteristics, and psychosocial vulnerabilities related to these conditions. The aim of this cross-sectional study was to examine Type D personality traits and life satisfaction among patients with BD-II and MDD and parents of patients. The study recruited/will recruit 30 patients with BD-II; 30 patients with MDD; 30 healthy control subjects; mothers and/or fathers of 30 healthy control subjects, mothers and/or fathers of 30 patients with BD-II, and mothers and/or fathers of 30 patients with MDD who are in remission and receiving follow-up care at the Psychiatry Outpatient Clinic of Elazığ Fethi Sekin City Hospital, Turkey (By Dilek ÖRÜM -Associate Professor of Psychiatry, dr.dilekulukan@gmail.com). Sociodemographic characteristics, Type D personality traits, general psychiatric symptoms, and life satisfaction assessed/will be assessed using validated self-report measures, including the Type D Personality Scale (DS14), the Brief Psychiatric Rating Scale (BPRS), and the Adult Life Satisfaction Scale (ALSS).

The primary objective was/is to compare Type D personality characteristics and life satisfaction levels between patients with MDD and BD-II and between their parents. Secondary objectives included/include investigating the associations between Type D personality traits, psychiatric symptom severity, and life satisfaction. The findings may contribute to a better understanding of familial psychological characteristics associated with mood disorders and may help identify potential psychosocial targets for preventive and supportive interventions among family members of affected individuals.

Panoramica dello studio

Descrizione dettagliata

Bipolar Disorder Type II (BD-II) and Major Depressive Disorder (MDD) are chronic mood disorders that contribute substantially to global disability, psychosocial impairment, and reduced quality of life. BD-II is characterized by recurrent major depressive episodes and at least one hypomanic episode, whereas MDD is characterized by recurrent depressive episodes without a history of mania or hypomania. Although both disorders share several clinical features, they differ in course, prognosis, treatment approaches, and familial aggregation patterns. Family and twin studies have consistently demonstrated that genetic and familial factors contribute significantly to the development of mood disorders. Consequently, first-degree relatives of individuals with mood disorders may exhibit subclinical affective traits, maladaptive personality characteristics, and psychosocial difficulties even in the absence of a diagnosable psychiatric disorder.

Type D ("distressed") personality is a stable personality construct characterized by the coexistence of two major traits: negative affectivity and social inhibition. Individuals with Type D personality tend to experience persistent negative emotions while simultaneously suppressing emotional expression in social interactions. Previous studies have shown that Type D personality is associated with increased psychological distress, anxiety, depressive symptoms, poorer coping abilities, lower quality of life, and adverse health outcomes. Similarly, life satisfaction is an important indicator of subjective well-being and psychological adjustment, and it may be influenced by both personality characteristics and familial vulnerability factors.

Although Type D personality has been investigated in patients with various psychiatric disorders, including mood disorders, little is known about the prevalence and clinical significance of Type D personality traits among parents of individuals diagnosed with BD-II or MDD. Furthermore, no study has directly compared Type D personality characteristics, psychiatric symptom severity, and life satisfaction among parents of patients with these two mood disorders. Understanding these familial psychological characteristics may provide important insights into the broader psychosocial and hereditary dimensions of mood disorders.

The present study was designed as a cross-sectional observational study conducted at the Psychiatry Outpatient Clinic of Elazığ Fethi Sekin City Hospital, Turkey. All participants included in the study were/will be recruited by MD Dilek ÖRÜM (Associate Professor of Psychiatry, dr.dilekulukan@gmail.com). The study recruited/will recruit 30 patients with BD-II; 30 patients with MDD; 30 healthy control subjects; mothers and/or fathers of 30 healthy control subjects, mothers and/or fathers of 30 patients with BD-II, and mothers and/or fathers of 30 patients with MDD who are in remission and receiving follow-up care at the Psychiatry Outpatient Clinic of Elazığ Fethi Sekin City Hospital, Turkey. The psychiatric diagnoses were made according to Text Revision of Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria. To minimize the influence of acute illness-related factors, only parents of patients who are currently in remission will be included. Parents with active psychiatric disorders, a history of major psychiatric illness, significant neurological disorders affecting cognition, or severe medical illnesses will be excluded.

All participants completed/will complete a sociodemographic data form and a battery of validated psychometric instruments. Type D personality characteristics will be assessed using the Type D Personality Scale (DS14), which evaluates negative affectivity and social inhibition. General psychiatric symptom severity will be evaluated using the Brief Psychiatric Rating Scale (BPRS). Subjective well-being and life satisfaction will be assessed using the Adult Life Satisfaction Scale (ALSS). Sociodemographic variables including age, sex, marital status, and educational level will also be collected.

The primary objective of the study was/is to compare Type D personality traits and life satisfaction levels between patients with BD-II-MDD and parents of patients with BD-II and parents of patients with MDD. Secondary objectives include/d examining the relationships between Type D personality dimensions, psychiatric symptom severity, and life satisfaction within each group and across the entire sample. The study additionally aims to identify demographic and clinical factors associated with life satisfaction among parents of individuals with mood disorders.

The study hypothesizes/d that parents of patients with BD-II will demonstrate higher levels of Type D personality traits and lower levels of life satisfaction than parents of patients with MDD. It was/is also hypothesized that greater Type D personality characteristics was associated/will be associated with increased psychiatric symptoms and lower life satisfaction.

Statistical analyses will be performed using SPSS 26.version software. Descriptive statistics will summarize demographic and clinical characteristics. Group comparisons will be conducted using chi-square or Fisher's exact tests for categorical variables and independent-samples t-tests or Mann-Whitney U tests for continuous variables, depending on data distribution. Correlation and regression analyses will be performed to investigate associations between Type D personality traits, psychiatric symptoms, and life satisfaction. Statistical significance will be set at p < 0.05.

The findings of this study may contribute to a better understanding of the familial psychological characteristics associated with mood disorders and may help identify potential targets for preventive, supportive, and psychosocial interventions among family members of affected individuals. By exploring the relationship between Type D personality and life satisfaction in parents of patients with BD-II and MDD, this study seeks to expand current knowledge regarding familial vulnerability factors and psychosocial outcomes related to mood disorders.

Tipo di studio

Osservativo

Iscrizione (Stimato)

180

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Mehmet Hamdi Örüm, MD, Associate Professor
  • Numero di telefono: +905382207558
  • Email: mhorum@hotmail.com

Backup dei contatti dello studio

Luoghi di studio

      • Elâzığ, Turchia (Türkiye), 23200
        • Reclutamento
        • Elazığ Fethi Sekin City Hospital
        • Contatto:
        • Contatto:
          • Mehmet Hamdi Örüm, MD Associate Professor
          • Numero di telefono: +905382207558
          • Email: mhorum@hotmail.com
        • Sub-investigatore:
          • Dilek Örüm, Associate Professor, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population consisted of adult participants aged above 18 years. The bipolar disorder type II (BD-II) group included consecutive patients diagnosed with BD-II and the major depressive disorder (MDD) group included consecutive patients diagnosed with MDD according to DSM-5-TR criteria who were admitted to the psychiatry outpatient clinic of Elazığ Fethi Sekin City Hospital (Turkey). The healthy control (HC) group consisted of individuals from the general population who applied to the hospital medical board and had no current or past psychiatric or significant medical disorders. Psychiatrically healthy mothers and/or fathers of members of the BD-II, MDD, and HC groups were also included in the study. All participants provided informed consent prior to enrollment.

Descrizione

  1. For Bipolar Disorder Type II (BD-II) Group:

    *Inclusion Criteria:

    • Diagnosis of BD-II according to DSM-5-TR
    • Remission period
    • Age ≥ 18 years
    • Provided informed consent

    For Bipolar Disorder Type II (BD-II) Group:

    *Exclusion Criteria:

    • Hypertension
    • Diabetes mellitus
    • Chronic kidney disease
    • Rheumatoid arthritis
    • Systemic lupus erythematosus
    • Cardiac illness
    • Severe neurological disorders
    • Immunological or systemic illness
    • Primary psychiatric disorders other than BD-II and not in remission for BD-II
    • Alcohol/drug/substance use
  2. For Major Depressive Disorder (MDD) Group:

    *Inclusion Criteria:

    • Diagnosis of MDD according to DSM-5-TR
    • Remission period
    • Age ≥ 18 years
    • Provided informed consent

    For Major Depressive Disorder (MDD) Group:

    • Exclusion Criteria:

      • Hypertension
      • Diabetes mellitus
      • Chronic kidney disease
      • Rheumatoid arthritis
      • Systemic lupus erythematosus
      • Cardiac illness
      • Severe neurological disorders
      • Immunological or systemic illness
      • Primary psychiatric disorders other than MDD and not in remission for MDD
      • Alcohol/drug/substance use
  3. For Healthy Control (HC) Group:

    *Inclusion Criteria:

    • No psychiatric diagnosis
    • No systemic or immunological illness
    • Medication-free for at least one month
    • Age ≥ 18 years
    • Provided informed consent

    For Healthy Control (HC) Group:

    *Exclusion Criteria:

    • Hypertension
    • Diabetes mellitus
    • Chronic kidney disease
    • Rheumatoid arthritis
    • Systemic lupus erythematosus
    • Cardiac illness
    • Severe neurological disorders
    • Immunological or systemic illness
    • Having psychiatric disorders
    • Alcohol/drug/substance use
  4. For Healthy Father and/or Mother of Bipolar Disorder Type II (BD-II) Group:

    *Inclusion Criteria:

    • No psychiatric diagnosis
    • No systemic or immunological illness
    • Medication-free for at least one month
    • Age ≥ 18 years
    • Provided informed consent

    For Healthy Father and/or Mother of Bipolar Disorder Type II (BD-II) Group:

    *Exclusion Criteria:

    • Hypertension

    • Diabetes mellitus
    • Chronic kidney disease
    • Rheumatoid arthritis
    • Systemic lupus erythematosus
    • Cardiac illness
    • Severe neurological disorders
    • Immunological or systemic illness
    • Having psychiatric disorders
    • Alcohol/drug/substance use
  5. For Healthy Father and/or Mother of Major Depressive Disorder (MDD) Group:

    *Inclusion Criteria:

    • No psychiatric diagnosis
    • No systemic or immunological illness
    • Medication-free for at least one month
    • Age ≥ 18 years
    • Provided informed consent

    For Healthy Father and/or Mother of Major Depressive Disorder (MDD) Group:

    *Exclusion Criteria:

    • Hypertension

    • Diabetes mellitus

    • Chronic kidney disease

    • Rheumatoid arthritis

    • Systemic lupus erythematosus

    • Cardiac illness

    • Severe neurological disorders

    • Immunological or systemic illness
    • Having psychiatric disorders
    • Alcohol/drug/substance use
  6. For Healthy Father and/or Mother of Healthy Control (HC) Group:

    *Inclusion Criteria:

    • No psychiatric diagnosis

    • No systemic or immunological illness

    • Medication-free for at least one month
    • Age ≥ 18 years
    • Provided informed consent

    For Healthy Father and/or Mother of Healthy Control (HC) Group:

    *Exclusion Criteria:

    • Hypertension
    • Diabetes mellitus
    • Chronic kidney disease
    • Rheumatoid arthritis
    • Systemic lupus erythematosus
    • Cardiac illness
    • Severe neurological disorders
    • Immunological or systemic illness
    • Having psychiatric disorders
    • Alcohol/drug/substance use

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Bipolar Disorder Type II (BD-II)
Adult patients diagnosed with Bipolar Disorder Type II (BD-II) according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria. Patients with BD-II must have a history of at least one hypomanic episode and one major depressive episode and must be in remission at the time of study participation, with no current hypomanic, depressive, or mixed episode. Patients with active psychiatric disorders, a history of major psychiatric disorders, significant neurological disorders affecting cognitive functioning, or severe medical illnesses excluded/will be excluded. Participants evaluated/will be evaluated once in a cross-sectional assessment. No intervention assigned/will be assigned by the study protocol. Assessments will include a sociodemographic data form, the Type D Personality Scale (DS14), the Brief Psychiatric Rating Scale (BPRS), and the Adult Life Satisfaction Scale (ALSS).
Major Depressive Disorder (MDD)
Adult patients diagnosed with Major Depressive Disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria. Patients with MDD must have a history of at least one major depressive episode and must be in remission at the time of study participation, with no current major depressive episode. Patients with a current or lifetime diagnosis of bipolar disorder, schizophrenia spectrum or other psychotic disorders, active psychiatric disorders requiring immediate treatment, significant neurological disorders affecting cognitive functioning, or severe medical illnesses excluded/will be excluded. Participants evaluated/will be evaluated once in a cross-sectional assessment. No intervention assigned/will be assigned by the study protocol. Assessments will/included a sociodemographic data form, the Type D Personality Scale (DS14), the Brief Psychiatric Rating Scale (BPRS), and the Adult Life Satisfaction Scale (ALSS).
Healthy Control (HC)
Healthy control (HC) adult participants without any current or past psychiatric disorder enrolled/will be enrolled in the study. No intervention was administered/will be administered as part of the research protocol. Participants undergo/will undergo a baseline clinical evaluation. Clinical assessments in the HC group included/will include the Type D Personality Scale (DS14), the Brief Psychiatric Rating Scale (BPRS), and the Adult Life Satisfaction Scale (ALSS). Sociodemographic and clinical data was recorded/will be recorded for all participants.
Healthy Father and/or Mother of Bipolar Disorder Type II (BD-II) Participant
Adult participants without any current or past psychiatric disorder enrolled/will be enrolled in the study. No intervention was administered/will be administered as part of the research protocol. Participants undergone/will undergo a baseline clinical evaluation. Clinical assessments in the this group included/will include the Type D Personality Scale (DS14), the Brief Psychiatric Rating Scale (BPRS), and the Adult Life Satisfaction Scale (ALSS). Sociodemographic and clinical data was recorded/will be recorded for all participants.
Healthy Father and/or Mother of Major Depressive Disorder (MDD) Participant
Adult participants without any current or past psychiatric disorder enrolled/will be enrolled in the study. No intervention was administered/will be administered as part of the research protocol. Participants undergone/will undergo a baseline clinical evaluation. Clinical assessments in the this group included/will include the Type D Personality Scale (DS14), the Brief Psychiatric Rating Scale (BPRS), and the Adult Life Satisfaction Scale (ALSS). Sociodemographic and clinical data was recorded/will be recorded for all participants.
Healthy Father and/or Mother of Healthy Control (HC) Participant
Adult participants without any current or past psychiatric disorder enrolled/will be enrolled in the study. No intervention was administered/will be administered as part of the research protocol. Participants undergone/will undergo a baseline clinical evaluation. Clinical assessments in the this group included/will include the Type D Personality Scale (DS14), the Brief Psychiatric Rating Scale (BPRS), and the Adult Life Satisfaction Scale (ALSS). Sociodemographic and clinical data was recorded/will be recorded for all participants.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Type D Personality Scale (DS14)
Lasso di tempo: At hospital admission (baseline)
The Type D Personality Scale (DS14) was developed by Denollet in 2005. The validity and reliability of the Turkish version among Turkish hemodialysis patients were established by Alçelik et al. The DS14 is a 14-item self-report instrument consisting of two 7-item subscales that assess Negative Affectivity (NA) (items 2, 4, 5, 7, 9, 12, and 13) and Social Inhibition (SI) (items 1, 3, 6, 8, 10, 11, and 14). Items 1 and 3 are reverse scored. Each item is rated on a 5-point Likert scale ranging from 0 ("false") to 4 ("true"), with the intermediate response options being "rather false," "neutral," and "rather true." Scores for each subscale range from 0 to 28, and a score of ≥10 on each subscale is considered the established cutoff value. In the Turkish validation study, the Cronbach's alpha coefficients were 0.82 for the Negative Affectivity subscale and 0.81 for the Social Inhibition subscale. The test-retest reliability coefficients were 0.84 and 0.78, respectively.
At hospital admission (baseline)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Brief Psychiatric Rating Scale (BPRS)
Lasso di tempo: At hospital admission (baseline)
The Brief Psychiatric Rating Scale (BPRS) is an 18-item Likert-type clinician-administered instrument with established validity and reliability in Turkish. It is used to assess the severity of psychiatric symptoms following a brief clinical interview and to evaluate treatment response over time. Higher scores indicate greater psychiatric symptom severity. The BPRS is widely used to measure the severity and changes in psychotic symptoms, as well as certain depressive symptoms, in individuals with schizophrenia, bipolar disorder, and other psychotic disorders, and to assess the effectiveness of psychiatric treatment.
At hospital admission (baseline)
Adult Life Satisfaction Scale (ALSS)
Lasso di tempo: At hospital admission (baseline)
The Adult Life Satisfaction Scale (ALSS) is a 21-item self-report instrument developed within the Turkish cultural context to assess life satisfaction in adults. The scale uses a 5-point Likert-type response format and comprises five dimensions: general life satisfaction, relationship satisfaction, self-satisfaction, satisfaction with the social environment, and job satisfaction. Total scores range from 21 to 105, with higher scores indicating greater perceived life satisfaction and more positive evaluations of one's own life. In the present study, the overall internal consistency of the ALSS was high, with a Cronbach's alpha coefficient of 0.87.
At hospital admission (baseline)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Mehmet Hamdi Örüm, Associate Professor, MD, Elazığ Mental Health and Diseases Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

23 dicembre 2024

Completamento primario (Stimato)

24 dicembre 2026

Completamento dello studio (Stimato)

24 dicembre 2026

Date di iscrizione allo studio

Primo inviato

25 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

25 giugno 2026

Primo Inserito (Effettivo)

1 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Descrizione del piano IPD

Deidentified individual participant data (IPD) underlying the results reported in this study (including demographic variables, Type D Personality Scale (DS14), Brief Psychiatric Rating Scale (BPRS), Adult Life Satisfaction Scale (ALSS)) will be made available to qualified researchers upon reasonable request for academic purposes. Data will be shared after removal of all direct identifiers and in accordance with applicable ethical approvals and data protection regulations. Access to the data will require a methodologically sound research proposal and a data use agreement. Requests should be directed to the corresponding author.

Periodo di condivisione IPD

Data will be available beginning 6 months after publication and will remain available for 5 years.

Criteri di accesso alla condivisione IPD

Access will be granted to researchers who provide a methodologically sound proposal. Requests must be approved by the principal investigator and may require a data use agreement in accordance with institutional and ethical regulations.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi